Women with a benign breast disease (BBD) have an increased risk of subsequent breast carcinoma. Information is scarce regarding the characteristics of breast carcinomas diagnosed after a BBD. Our aim was to point out the differences in clinical and histologic characteristics of breast carcinomas diagnosed in women with and without a previous pathologic diagnosis of BBD in the context of populationbased mammography screening. Retrospective cohort study of all women aged 50-69 years who were screened at least once in a population-based screening program in Spain, between 1994 and 2011 and followed up until December 2012.
regression was used to estimate the odds ratio (OR) and 95% confidence intervals (95%CI) of occurrence of selected histologic characteristics of breast carcinomas in women with and without a previous BBD. Women with a previous BBD had a higher proportion of ductal carcinoma in situ (DCIS) compared with women without a BBD (22.1% and 13.6%, respectively). Among those diagnosed with an invasive breast carcinoma, women with previous BBD were more likely to be diagnosed with carcinomas sized >2 cm (OR = 1.46; 95%CI = 1.03-2.08), metastatic positive (OR = 2.66; 95%CI = 1.21-5.86), and with a high Ki-67 proliferation rate (OR = 1.93; 95%CI = 1.24-2.99). No differences were found across histologic subtypes of BBD. Screening participants with a previous pathologic diagnosis of BBD had a higher proportion of DCIS. However, invasive carcinomas detected in women with a BBD were associated with clinical and histologic characteristics conferring a worst prognosis.
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| INTRODUCTION
Population-based mammography screening for breast cancer entails a number of benign breast findings at biopsy recommendation to rule out malignancy, referred to as benign breast disease (BBD). It is estimated that 1.8% of women aged 50-69 years participating regularly in the mammographic screening program in Spain will have a biopsy recommendation with a benign outcome. 1 Women with BBD are at a substantially increased risk of subsequent breast cancer. [2] [3] [4] [5] Among women with a BBD, nonproliferative breast diseases have been shown to have a moderate elevated risk of subsequent breast cancer, 2 but the risk has been found to be higher for proliferative disease without atypia, and highest for proliferative disease with atypia. [2] [3] [4] However, the European guidelines for quality assurance in breast cancer screening and diagnosis do not provide specific recommendations for the clinical management of women with a pathologic diagnosis of BBD at mammography screening. 6 Due to their increased risk of breast cancer, women with BBD may benefit from a personalized breast cancer screening strategy.
These strategies aim at improving the balance of benefits and harms of breast cancer screening by offering different frequency and modality of screening to women invited based on their breast cancer risk. 7, 8 There is lack of evidence on whether the clinical and histologic characteristics of breast carcinomas may differ in women with and without a previous BBD. [9] [10] [11] The studies yielded contradictory results, and none of them is performed in the context of population-based mammography screening. We aimed to point out the differences in clinical and histologic characteristics of breast cancers diagnosed in women with and without a previous pathologic diagnosis of BBD in the context of population-based mammography screening in Spain. 
| METHODS

| Setting and study population
| Statistical analyses
For simplicity of presentation of results, the study variables were Because information on breast cancer characteristics was missing for some women in the study population, we performed a sensitivity analysis to compare the distribution of age at last screening exam, detection mode, and year at last screening exam in women with and without missing information on these variables.
| RESULTS
We analyzed 6645 women with a diagnosis of breast cancer, of whom 238 (3.6%) had a previous pathologic diagnosis of BBD.
Among the breast carcinomas, 4450 (67.0%) were screen detected and 2195 (33.0%) were interval carcinomas. A higher proportion of DCIS was found in women with than in women without a previous BBD (22.1% and 13.6%, respectively; P < .05; Table 1 ). No significant differences were found in age distribution, or mode of detection between women with and without a BBD (Table 1) .
Among invasive breast carcinomas, women with previous BBD had a higher proportion of invasive carcinomas that were sized >2 cm (36.7% vs 26.4%), metastatic positive (5.2% vs 1.7%, respectively), and with a high Ki-67 proliferation rate (50.5% vs 33.7%, respectively), compared with women without a BBD ( T Shown in Table 4 are the clinical and histologic characteristics of breast carcinomas by subcategory of pathologically diagnosed BBD.
Compared with women without a BBD, women with nonproliferative lesions had a higher proportion of DCIS (Table 4) (Table 5 ), compared with women without a BBD.
| DISCUSSION
Women with a previous pathologic diagnosis of BBD were more likely to be diagnosed with a DCIS rather than an invasive carcinoma compared with women without a BBD. However, invasive carcinomas diagnosed in women with a BBD were associated with worst prognosis characteristics such as size >2 cm, positive distant metastasis, and high Ki-67 proliferation rate. To our knowledge, this is the first study to compare the clinical and histologic characteristics of breast carcinomas in population-based mammography screening in women with and without a previous BBD.
Previous research indicates that women with a BBD are at a higher risk of developing subsequent breast carcinoma. We found a higher proportion of DCIS in breast carcinomas diagnosed in women with a BBD, which has previously been reported. 10 The difference may indicate that women with a pathologically diagnosed BBD are more likely to be aware of their health status and attend biennial screening regularly. However, the analyses stratified by detection mode showed a similarly increased proportion of DCIS in women with a BBD for screen detected and interval carcinomas.
It is important to remark that following the European Guidelines, women with a BBD detected at screening do not follow different screening recommendations than women with negative screening tests. On a previously published work, we found a higher proportion of DCIS in women with a previous biopsy with a benign result compared with women with negative screening tests only. 19 Also, we found no differences in the proportion of DCIS across the BBD subtypes, which is consistent with previous results.
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The role of tumor size in the differences found between women with and without a BBD has yielded contradictory results. The above-mentioned study by Mitro et al showed no differences in tumor size between women with and without a BBD, whereas the study carried out in Spain by Domingo et al showed a higher proportion of tumors sized >2 cm in women with a biopsy with benign result compared with women with negative screening tests. 10, 19 In agreement with previously reported data, we found no differences in tumor size across subtypes of BBD. Indicates the pairs that are significantly different within each multiple pairwise comparison.
We found that ER, PR, and HER2 receptor status were not histologic characteristics distinctive between women with and without a BBD. Our findings of an absence of differences in the hormone receptor status are in agreement with a previous study. 10 Neither did we find differences in the proportion of ER+, nor PR+ invasive breast carcinomas across BBD subtypes, which is in agreement with a previous study, 9 but not with other 11 that found a higher proportion of In our study population, 3.6% of breast carcinomas were diagnosed in women with a previous pathologic diagnosis of BBD. A study assessing breast cancer risk in women targeted for mammography screening reported that the proportion of breast carcinomas diagnosed in women with a previous BBD, that was not self-reported, was 3.7%. 21 Studies carried out in a clinical setting have reported larger numbers of breast carcinomas in women with a previous pathologic diagnosis of BBD. 11 However, comparisons with clinical studies in absolute numbers are difficult because they lack a balanced reference population of women without a BBD. Most differences found between our study and previously published clinical studies could be explained by the study setting. First, the basis of our study population is a cohort of asymptomatic women biennially screened for breast cancer, which substantially differs from clinical studies where most women had a biopsy recommendation because of self-declared symptoms. Second, we did not include in our analyses BBD that were self-reported at the time of screening mammography. This inclusion criteria ensures that all BBD included for analyses was radiologically and pathologically confirmed and diagnosed in asymptomatic women, which is the basis of a population-based screening program.
A major strength of this study is that data were obtained from a well-established population-based screening program with an average participation of 67% of invited women, and a reattendance rate of 91.2%. 12 We analyzed data from over 16-years of follow-up and 550.000 women aged 50-69 years screened at least once in the program, which minimizes selection bias. However, the study has several limitations. First, the study was limited by the number of women with missing information for some histologic characteristics, particularly hormonal receptors and Ki-67 status, which limits some interpretations. The sensitivity analyses showed a higher proportion of missing data on the earliest years after start of the screening program, because information on ER, PR, HER2, or Ki-67 was not routinely collected at that time (supplementary material). We also found that the proportion of missing data was larger among interval carcinomas, which was expected given that information on interval carcinomas was identified by linkage with external sources of information that do not systematically collect information on breast cancers characteristics. Also, we found small variations in the age distribution between women with and without missing information, although the distribution was consistently similar between women with available data and women with missing information on clinical and histologic characteristics. Second, we had a reduced number of women with breast carcinoma after a BBD, which entails a small sample size for some subgroup analyses. Consequently, some results should be interpreted with care. Another limitation of the study is that women screened in 2011 were followed up until December 2012 for interval carcinomas, which shortens the usual 24 months follow-up period.
However, because the aim of the study was not to estimate breast cancer incidence but to compare the clinical and histologic characteristics of breast carcinomas among women with and without previous BBD, it is unlikely that a shorter follow-up for interval carcinomas has any effect on the characteristics studied.
| CONCLUSION S
Our study suggests that although women with a pathologic diagnosis of BBD are more likely to develop a DCIS compared with women Adjusted for detection mode (screen detected or interval cancer), age at last screen, and calendar year at last screen.
without a BBD, their invasive carcinomas are associated with clinical and histologic characteristics conferring a worst prognosis, such as tumor size >2 cm, distant metastasis, and a high Ki-67 proliferation rate. In addition to increasing the breast cancer risk, BBD pathologically diagnosed at screening could predict 2 types of breast carcinomas; the slow-growing type identified by a higher proportion of DCIS, but also breast cancers with worse prognosis characteristics among those with an invasive carcinoma. This information widens the knowledge about the natural history of breast carcinomas in women with a previous BBD diagnosed at screening. Women with a BBD could benefit from a closer surveillance that should be considered when more personalized screening strategies are discussed.
